• Oaktree Acquisition III Life Sciences shareholders approved extending the business combination deadline at the October 23, 2026, extraordinary general meeting.
• The amendment extended the deadline from October 25, 2026, to November 25, 2026.
• Shareholders also authorized optional monthly extensions at the sponsor's request, through May 25, 2027, at the latest.
• The adjournment proposal was not put to a vote because the extension proposal secured sufficient support.
• Holders exercised redemption rights on 11,331,102 Class A ordinary shares at approximately $10.805 each, totaling approximately $122.44 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oaktree Acquisition III Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-430980), on October 26, 2026, and is solely responsible for the information contained therein.